Design + Industry is now ISO 13485:2016 certified
BioMelbourne Network member Design + Industry (D+I) is proud to announce that they have achieved ISO 13485:2016 certification — the culmination of a four-year effort and recognition of their commitment to design and engineering excellence in the development…
2019 ARCS Annual Conference: call for session and program proposals extended
Interested parties from industry, research institutions, government and academia involved in development through to commercialisation of therapeutics (from bench to bedside) are invited to submit session proposals and program suggestions for the 2019 ARCS Annual Conference to be…
BioEYES looking for industry partners
3 December 2018 BioEYES Australia is a science outreach program that covers curricula in genetics, cell biology and developmental biology, but more importantly excites students about the thrill of scientific discovery. Over a 1 week incursion, students set…
ARC Centre for Personalised Therapeutics Technologies launches in Melbourne
22 November 2018 The ARC Centre for Personalised Therapeutics Technologies launched in Melbourne this week. The centre, headquartered at the Department of Pharmacology and Therapeutics at the University of Melbourne, aims to advance and deploy new technologies that will remove…
Novartis and BioCurate announce first collaboration to accelerate early stage drug discovery
31 October 2018 Biomedical research company BioCurate Pty Ltd and Novartis today announced that they will collaborate on early stage drug discovery projects that have potential to address an unmet need. This collaboration marks BioCurate’s first with the…
Watermark a first-mover with customised website live chat platform
Being on the leading edge of innovation and intellectual property, Watermark is paving the digital path for IP attorney and legal services firms with the unveiling of a website chat bot. Executive General Manager Mark Bisset says the…
Immutep enters into clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer
Immutep Limited is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc., to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha…
Burnet’s qDOS Lab a new approach to bringing innovative technologies to market
Fast-tracking innovative technologies through early proof-of-concept and feasibility stages is a key aim of Burnet Institute’s new initiative, the Quick Development of Solutions Lab (qDOS Lab). Nurturing technologies through key early-stage development phases by adopting a market led approach is a primary focus…
What to do when an R&D tax incentive claim goes bad
The R&D tax incentive program is the Government’s largest program designed to support business innovation. It has been reviewed multiple times, with each review concluding it provides significant benefits to the Australian economy, far beyond the cost. AusIndustry…
Sienna appoints exclusive distribution partner for mainland China
Sienna Cancer Diagnostics Ltd has appointed Shaanxi GaoYuan In Vitro Diagnostic Reagents Co. (“GaoYuan”) as the Company’s exclusive distribution partner for mainland China. The distribution agreement for mainland China is a milestone in Sienna’s geographical expansion strategy. The agreement…
Immutep TACTI-mel patient recruitment completed, operational update & Canadian IMP731 patent
Immutep today reports in its operational update that the final patient in Part B of the ongoing TACTI-mel Phase I clinical trial in Australia has now been recruited and is receiving treatment. Patients will be treated for up…
BioCurate launches first round of project investments
BioCurate Pty Ltd has achieved an important milestone announcing investments in six early drug discovery projects from research groups at The University of Melbourne and Monash University. These projects represent the first tranche of investments for BioCurate: Dr…
